Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;36(4):628-644.
doi: 10.1681/ASN.0000000535. Epub 2024 Nov 12.

Misprocessing of α -Galactosidase A, Endoplasmic Reticulum Stress, and the Unfolded Protein Response

Affiliations

Misprocessing of α -Galactosidase A, Endoplasmic Reticulum Stress, and the Unfolded Protein Response

Martina Živná et al. J Am Soc Nephrol. .

Abstract

Key Points:

  1. The clinical significance of a number of missense variants of α-galactosidase A is often ambiguous.

  2. Defective proteostasis of some missense α-galactosidase A variants induced chronic endoplasmic reticulum stress and the unfolded protein response.

  3. Endoplasmic reticulum stress and the unfolded protein response may explain clinical manifestations of non-classic Fabry disease.

Background: Classic Fabry disease is caused by GLA mutations that result in loss of enzymatic activity of α-galactosidase A, lysosomal storage of globotriaosylceramide, and a resulting multisystemic disease. In non-classic Fabry disease, patients have some preserved α-galactosidase A activity and a milder disease course. Heterozygous female patients may also be affected. While Fabry disease pathogenesis has been mostly attributed to catalytic deficiency of mutated α-galactosidase A, lysosomal storage, and impairment of lysosomal functions, other pathogenic factors may contribute, especially in nonclassic Fabry disease.

Methods: We characterized the genetic, clinical, biochemical, molecular, cellular, and organ pathology correlates of the p.L394P α-galactosidase A variant that was identified initially in six individuals with kidney failure by the Czech national screening program for Fabry disease and by further screening in an additional 24 family members.

Results: Clinical findings in affected male patients revealed a milder clinical course, with approximately 15% residual α-galactosidase A activity with normal plasma lyso-globotriaosylceramide levels and abnormally low ratio of these values. None of the four available kidney biopsies showed lysosomal storage. Laboratory investigations documented intracellular retention of mutated α-galactosidase A with resulting endoplasmic reticulum stress and the unfolded protein response, which were alleviated with BRD4780, a small molecule clearing misfolded proteins from the early secretory compartment. We observed similar findings of endoplasmic reticulum stress and unfolded protein response in five kidney biopsies with several other classic and non-classic Fabry disease missense α-galactosidase A variants.

Conclusions: We identified defective proteostasis of mutated α-galactosidase A resulting in chronic endoplasmic reticulum stress and unfolded protein response of α-galactosidase A expressing cells as a contributor to Fabry disease pathogenesis.

PubMed Disclaimer

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/E956.

References

    1. Cairns T, Müntze J, Gernert J, Spingler L, Nordbeck P, Wanner C. Hot topics in Fabry disease. Postgrad Med J. 2018;94(1118):709–713. doi:10.1136/postgradmedj-2018-136056 - DOI - PMC - PubMed
    1. Oder D, Nordbeck P, Wanner C. Long term treatment with enzyme replacement therapy in patients with Fabry disease. Nephron. 2016;134(1):30–36. doi:10.1159/000448968 - DOI - PubMed
    1. Dutra-Clarke M Tapia D Curtin E, et al. . Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy. Mol Genet Metab. 2021;132(2):S36. doi:10.1016/j.ymgme.2020.12.069 - DOI - PMC - PubMed
    1. Germain DP Hughes DA Nicholls K, et al. . Treatment of Fabry's disease with the pharmacologic chaperone migalastat. New Engl J Med. 2016;375(6):545–555. doi:10.1056/NEJMoa1510198 - DOI - PubMed
    1. Lenders M, Stappers F, Brand E. In vitro and in vivo amenability to migalastat in Fabry disease. Mol Ther Methods Clin Dev. 2020;19:24–34. doi:10.1016/j.omtm.2020.08.012 - DOI - PMC - PubMed

LinkOut - more resources